A phase 3 clinical study of teplizumab for treatment of children and adolescents with newly diagnosed type 1 diabetes
- Conditions
- Type 1 Diabetes (T1D)MedDRA version: 20.0 Level: LLT Classification code 10012594 Term: Diabetes System Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- EUCTR2018-004926-26-FR
- Lead Sponsor
- Provention Bio, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 300
1. Participant is male or female.
2. Participant is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study drug
administration.
3. Participant has received a diagnosis of T1D according to the criteria from the American Diabetes
Association (ADA)
4. Participant is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal
T1D diagnosis according to the ADA criteria.
5. Participant has a peak stimulated C-peptide of =0.2 pmol/mL from a 2-hour mixed meal tolerance
test (2h MMTT) at screening. (Note: This screening 2h MMTT must occur only after 6 days
following diagnosis to allow for reduction of metabolic instability.)
6. Participant has a positive result on testing for at least one of the following T1D-related
autoantibodies before randomization:
• Glutamic acid decarboxylase 65 (GAD65) autoantibodies
• Islet antigen 2 (IA-2) autoantibodies
• Zinc transporter 8 (ZnT8) autoantibodies
• Islet cell cytoplasmic autoantibodies (ICA) or
• Insulin autoantibodies (if testing obtained within the first 14 days of insulin treatment)
7. Female participants of childbearing potential must have a negative result on highly sensitive serum
(ß human chorionic gonadotropin [ß-HCG]) at screening and at randomization.
8. Sexually active participants must agree to adhere to the following contraceptive requirements:
• Sexually active females: unless surgically sterile, use 2 forms of contraception (including oral,
transdermal, injectable, or implanted contraceptives, intrauterine device, female condom,
diaphragm with spermicide, cervical cap, use of a condom by the sexual partner, or a sterile
sexual partner) continuously from 30 days before the first dose of study drug through the end
of the study.
• Sexually active males with partners of childbearing potential: use of barrier contraception in
addition to having their partners use another method of contraception from 1 week before each
study agent dose through 120 days (a complete spermatogenesis cycle) after receiving the last
dose in each treatment course.
9. Prior to receiving study drug, participant must be up to date with and/or agree to receive routine
age-appropriate immunizations and comply with the guidelines for immunosuppressed individuals
and those with chronic disease (diabetes mellitus) according to current local, regional and/or
country-specific guidelines.
10. Participant agrees not to receive other forms of experimental treatment during the study,
particularly agents that may be immune modulatory in nature and/or stimulate pancreatic ß cell
regeneration or insulin secretion
11. Participant and/or appropriate legal guardian must sign an informed consent form (ICF) and/or
assent according to local, regional and/or country-specific guidance for study participation.
Are the trial subjects under 1
1. Participant has known allergies, severe reaction, intolerance, hypersensitivity, or anaphylaxis to human, humanized, or murine monoclonal antibodies, teplizumab or any of its components or its excipients.
2. Participant has been an active participant in a therapeutic drug, invasive medical device, or vaccine clinical trial within 12 weeks before the first dose of drug.
3. Participant has significant renal, cardiac, vascular, pulmonary, gastrointestinal, neurologic, hematologic, rheumatologic, oncologic, psychiatric disease, or immune deficiency.
4. Participant has any autoimmune disease other than T1D (eg, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematous, with the exception of stable thyroid or celiac disease.
5. Participant has an active infection and/or fever =38.5°C (101.3°F) within the 48 hours prior to randomization, is prone to infections, or has chronic, recurrent or opportunistic infectious disease, including but not limited to renal, respiratory or skin infections, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis.
6. Participant has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
7. Participant has any of the following in regards to tuberculosis (TB): history of latent or active TB, signs and/or symptoms of TB, recent close contact with a person with known or suspected active TB, history of a chest X-ray consistent with active TB or old, inactive TB, hstory of a positive purified protein derivative skin test result (>10 mm induration) or at screening is positive or repeatedly indeterminate with an approved interferon-gamma
release assay (IGRA; eg, QuantiFERON-TB test); recent chest X-ray or one conducted at screening read by a qualified radiologist consistent with current, active TB or old, inactive TB
8. At screening, participant has a clinically active infection with EBV, including to but not limited to infectious mononucleosis, or an EBV viral load =10,000 copies per mL or per 106 lymphocytes obtained at screening.
9. At screening, participant has a clinically active infection with CMV or a CMV viral load 10,000 copies per mL or per 106 lymphocytes obtained at screening.
10. Participant has a diagnosis of significant liver disease or at screening alanine aminotransferase (ALT), aspartate aminotransferase (AST) >2X or total bilirubin (TBili) of >1.5X of the age- and sex-specific upper limit of normal (ULN) according to the central laboratory.
11. An individual has any of the following hematologic parameters:
• Lymphocyte count: <1000/µL
• Neutrophil count: <1000/µL
• Platelet count: <100,000 platelets/µL
• Hemoglobin: <10 g/dL
12. Current or prior treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high-dose inhaled, extensive topical, or systemic glucocorticoids.
13. Current or prior use of drugs other than insulin to treat hyperglycemia (eg, metformin, sulfony
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method